• 1
    Kim WR, Gross JB, Poterucha JJ, Locke GR, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. HEPATOLOGY 2001; 33: 201206.
  • 2
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19): 139.
  • 3
    Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S9S.
  • 4
    Orland JR, Wright TL, Cooper S. Acute hepatitis C. HEPATOLOGY 2001; 33: 321327.
  • 5
    Donahue JG, Munoz A, Ness PM, Brown DEJ, Yawn DH, McAllister HA Jr, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369373.
  • 6
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infection. N Engl J Med 1996; 334: 16851690.
  • 7
    Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, Taylor PE, et al. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 1991; 325: 13251329.
  • 8
    National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994, NHANES III. Hyattsville, MD: National Center for Health Statistics, 1996.
  • 9
    Alter MJ. Hepatitis C: a sleeping giant? Am J Med 1991; 91: 112S115S.
  • 10
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331338.
  • 11
    HCUPnet, Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 1994–2001. Rockville, MD: Agency for Healthcare Research and Quality, 2004.
  • 12
    National Center for Health Statistics. National Ambulatory Medical Care Survey, 1994–2002. Hyattsville, MD: National Center for Health Statistics, 2004.
  • 13
    Verispan Source Prescription Audit. Physician Drug & Diagnosis Audit, 1993–2000. Newtown, PA: Verispan, 2004.
  • 14
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000; 31: 777782.
  • 15
    Shatin D, Schlech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care 2004; 10: 250256.
  • 16
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 15621569.
  • 17
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost-effectiveness of interferon alpha-2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 13181324.
  • 18
    Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis-C virus coinfection. Lancet 2003; 362: 17081713.